Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

LVMH has reclaimed its spot as the biggest company in Europe, overtaking Novo Nordisk after a significant drop in the ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.

Mads Krogsgaard Thomsen, CEO of Novo Nordisk Foundation, discusses European competitiveness.

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...